• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Vivos Therapeutics Inc.

    12/30/24 5:39:17 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Vivos Therapeutics Inc.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    92859E207

    (CUSIP Number)


    12/22/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92859E207


    1Names of Reporting Persons

    Mitchell P. Kopin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,315.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    266,315.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,315.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    92859E207


    1Names of Reporting Persons

    Daniel B. Asher
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,315.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    266,315.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,315.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    92859E207


    1Names of Reporting Persons

    Intracoastal Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,315.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    266,315.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,315.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Vivos Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.
    (c)Citizenship:

    Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
    (d)Title of class of securities:

    Common stock, par value $0.0001 per share
    (e)CUSIP No.:

    92859E207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Immediately following the execution of the Securities Purchase Agreement with the Issuer on December 22, 2024 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on December 23, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 354,610 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 6.4% of the Common Stock, based on (1) 5,180,300 shares of Common Stock outstanding prior to the execution of the SPA, as reported to the Reporting Persons by the Issuer, plus (2) 354,610 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 354,610 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (the "Intracoastal Warrant") because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 709,220 shares of Common Stock. As of the close of business on December 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 297,315 shares of Common Stock, which consisted of (i) 228,610 shares of Common Stock held by Intracoastal and (ii) 68,705 shares of Common Stock issuable upon exercise of the Intracoastal Warrant, and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 5,180,300 shares of Common Stock outstanding prior to the execution of the SPA, as reported to the Reporting Persons by the Issuer, plus (2) 709,220 shares of Common Stock in the aggregate issued at the closing of transaction contemplated by the SPA and (3) 68,705 shares of Common Stock issuable upon exercise of the Intracoastal Warrant. The foregoing excludes 285,905 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 583,220 shares of Common Stock.
    (b)Percent of class:

    4.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    297,315

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    266,315

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11240.14.,A.-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mitchell P. Kopin
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin
    Date:12/30/2024
     
    Daniel B. Asher
     
    Signature:/s/ Daniel B. Asher
    Name/Title:Daniel B. Asher
    Date:12/30/2024
     
    Intracoastal Capital LLC
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin / Manager
    Date:12/30/2024
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement

    Get the next $VVOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

    Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00

    2/5/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

    LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to

    1/20/26 5:31:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

    LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered

    1/16/26 8:00:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Skaff Michael C claimed ownership of 1,342,498 shares (SEC Form 3)

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    6/20/25 5:54:04 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:47:13 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:43:54 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    2/6/26 4:05:34 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    1/20/26 4:05:35 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    1/16/26 4:05:42 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

    8/13/21 1:08:07 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

    5/18/21 10:44:01 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Financials

    Live finance-specific insights

    View All

    Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

    Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t

    11/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025. The Company will conduct a conference call at 5:00 pm Eastern time on November 19, 2025, to review the results and provide operational updates.

    11/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vivos Therapeutics Inc.

    SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

    9/24/24 2:59:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care